Benazepril
- TRADE NAMES: Cibace; Cibacen; Cibacene; Lotensin (Novartis); Lotensin HCT (Novartis); Lotrel (Novartis)
- INDICATIONS: Hypertension
- CLASS: Angiotensin-converting enzyme (ACE) inhibitor, Antihypertensive, Vasodilator
- HALF-LIFE: 10–11 hours
Allopurinol, Amifostine, Amiloride, Angiotensin II receptor blockers, Antacids, Antidiabetics, Antihypertensives, Azathioprine, Cyclosporine, Diazoxide, Diuretics, Eplerenone, Everolimus, Gold & Gold Compounds, Herbals, Lithium, MAO inhibitors, Methylphenidate, NSAIDs, Pentoxifylline, Phosphodiesterase 5 inhibitors, Potassium salts, Prostacyclin analogues, Rituximab, Sirolimus, Spironolactone, Temsirolimus, Tizanidine, Tolvaptan, Triamterene, Trimethoprim, Yohimbine
PREGNANCY CATEGORY: D
Lotrel is benazepril and amlodipine. Lotensin-HCT is benazepril and hydrochlorothiazide.
Hydrochlorothiazide is a sulfonamide and can be absorbed systemically. Sulfonamides can produce severe, possibly fatal, reactions such as toxic epidermal necrolysis and Stevens-Johnson syndrome.
Contra-indicated in patients with a history of angioedema with or without previous ACE inhibitor treatment.
See full prescribing information for complete boxed warning.
Please login to see the rest of this drug profile
Page last updated 03/15/2024
Symbol key
Incidence
- <1%
- 1-5%
- 5-10%
- 10-15%
- 15-20%
- 20-30%
- >30%
Warnings in other populations
- Breast feeding
- Geriatric
- Pediatric